-
-
-
-
-
-
-
Brookline Capital Markets Upgrades Intensity Therapeutics, Inc. (INTS) to Buy
-
-
-
-
-
-
-
Intensity Therapeutics, Inc. (INTS) Misses Q1 EPS by 4c
-
-
-
-
-
-
-
Intensity Therapeutics (INTS) Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

